<DOC>
	<DOCNO>NCT02274545</DOCNO>
	<brief_summary>H7N9 virus cause outbreak severe respiratory disease 2013-2014 China affect many old adult . This study evaluate safety immune response live attenuate H7N9 vaccine adult 50 70 year old .</brief_summary>
	<brief_title>Evaluating Safety Immunogenicity H7N9 Vaccine Prevention Influenza H7N9 Disease Adults 50 70 Years Old</brief_title>
	<detailed_description>H7N9 virus cause outbreak severe respiratory disease China 2013-2014 , associate severe respiratory illness , acute respiratory distress syndrome ( ARDS ) , intensive care unit ( ICU ) admission , death . The outbreak affect old adult highlight need vaccine effective population . Prior study demonstrate safety immunogenicity vaccination regimen administration experimental H7N9 vaccine ( H7N9 Anhui 2013/AA ca ) follow H7N9 inactivate vaccine young adult . This study evaluate safety immunogenicity similar vaccination regimen healthy adult , 50 70 year old , H7N9 seronegative . Participants admit inpatient unit 2 day receive first vaccination H7N9 Anhui 2013/AA ca vaccine . All participant receive one dose H7N9 vaccine , deliver nasal spray , Day 0 . While inpatient unit , study procedure include physical examination , medical history review , nasal swab , blood urine collection . On Day 9 , participant discharge inpatient unit provide meet certain medical criterion . If , remain isolation unit criterion meet . On Day 26 , participant readmitted inpatient unit , Day 28 , receive one dose H7N9 vaccine deliver nasal spray . Participants remain inpatient unit Day 37 take part study procedure occur first inpatient stay . On Day 56 , participant attend study visit blood collection nasal swab . On Day 98 , participant receive one dose inactivate subvirion H7N9 vaccine . They attend study visit Days 101 , 105 , 112 , 126 , 154 , 180 , include study procedure occur inpatient visit .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Influenza Birds</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Adult male nonpregnant female 50 year 70 year age inclusive . Children recruit enrol study apparent risk group , safety consideration need isolation . Are good health , determine medical history target physical examination ensure exist medical diagnosis condition ( except exclusionary ) stable . More information criterion find protocol . Agree storage blood specimens future research Available duration trial . Participants must willing able remain within Isolation Unit specify duration confinement . Willingness participate study evidence sign informed consent document Female participant childbearing potential must agree use effective birth control method duration study ( example , pharmacologic contraceptive include oral , parenteral , transcutaneous delivery ; condom spermicide ; diaphragm spermicide ; intrauterine device ; abstinence heterosexual intercourse ; surgical sterilization ) . All female participant consider childbearing potential except undergone hysterectomy menopause occur least 1 year prior study . Agrees participate another clinical trial investigational product entire duration study Pregnancy determine positive human choriogonadotropin ( betaHCG ) test Evidence clinically significant neurologic , cardiac , pulmonary , hepatic , rheumatologic , autoimmune , renal disease history , physical examination , and/or laboratory study include urine testing . Alanine aminotransferase ( ALT ) level great 2 time upper normal limit exclusionary baseline , prior vaccination . Any current illness require daily medication follow : vitamin , birth control , antihypertensive medication , antihistamine , antidepressant medication , cholesterol lower medication , treatment gastroesophageal reflux disease ( GERD ) , thyroid medication unless approve principal investigator . Behavioral cognitive impairment psychiatric disease opinion investigator affect ability participant understand cooperate study protocol Previous enrollment H7 H9 influenza vaccine trial study avian influenza vaccine Seropositive H7N9 influenza A virus ( serum HAI titer great 1:8 ) Positive urine drug toxicology test indicate narcotic use/dependency Have medical , occupational , family problem result alcohol illicit drug use past 12 month Other condition opinion investigator would jeopardize safety right participant trial would render participant unable comply protocol History anaphylaxis component H7N9 vaccine Allergy oseltamivir determine participant report Current diagnosis asthma reactive airway disease ( within past 2 year ) History GuillainBarr√© Syndrome Positive ELISA confirmatory Western blot test human immunodeficiency virus1 ( HIV1 ) Positive ELISA confirmatory test ( e.g. , recombinant immunoblot assay ) hepatitis C virus ( HCV ) Positive hepatitis B virus surface antigen ( HBsAg ) ELISA Known immunodeficiency syndrome Use corticosteroid ( exclude topical preparation ) immunosuppressive drug within 30 day prior vaccination Receipt live vaccine within 4 week kill vaccine within 2 week prior study vaccination History asplenia Receipt blood bloodderived product ( include immunoglobulin ) within 6 month prior study vaccination Current smoker unwilling stop smoking duration inpatient stay . A current smoker include anyone state currently smoke use amount tobacco product , include electronic cigarette . After admission unit , nicotine patch provide current smoker request inpatient portion study . Travel Southern Hemisphere within 14 day prior study vaccination Travel cruise ship within 14 day prior study vaccination Receipt another investigational vaccine drug within 30 day prior study vaccination Allergy egg , egg product , formaldehyde</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>